Efficacy of Notal Vision Home OCT demonstrated by a series of scientific and clinical work
Retrieved on:
星期三, 六月 29, 2022
Diagnosis, Artificial intelligence, Patient, Alarm monitoring center, Caregiver, GLOBE, Retina, BMC, OCT, Monitoring, ARVO, Doctor of Philosophy, National Eye Institute, AMD, NOA, FDA, Home, Jennifer Loewenstein, Compliance, BioMed Central, CNV, Disease management, Research, HOME, Choroidal neovascularization, Documentation, CEO, Robert A. Holekamp, Severe cognitive impairment, Association for Research in Vision and Ophthalmology, Technology, Longitudinal, AI, SD, Medicare, National Eye, Inc., Review, Health, Home Monitoring Aréna, Macular degeneration, Knut S. Heier, Association, Risk, Therapy, Physician, American Medical Association, Program, Algorithm, Medical device, Medical imaging, Eye, Ophthalmology, MD
Home monitoring using standard of care OCT technology is expected to optimize treatment regimens for these patients and provide better vision outcomes.
Key Points:
- Home monitoring using standard of care OCT technology is expected to optimize treatment regimens for these patients and provide better vision outcomes.
- The investigational Notal Home OCT device, which received an FDA breakthrough designation, is the leading pipeline technology for monitoring wet AMD treatments.
- A series of studies using Notal Visions Home OCT have shown that the device is effective in overcoming each of these challenges.
- Notal Visions Home OCT has the potential to support current and future advances in retinal disease management.